Company: TAK
Filing Date: 2025-01-30
Form Type: 6-K
Source: 0001395064-25-000002
Chunk: 6

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-01-30
Form: 6-K
Chunk 6
---
 +5.6% CER).

Sales of ENTYVIO (for ulcerative colitis (“UC”) and Crohn’s disease (“CD”)) were JPY 699.0 billion (JPY +79.7 billion and +12.9% AER, +6.6% CER). Sales in the U.S. were JPY 476.0 billion (JPY +44.2 billion and +10.2% AER). The increase was due to favorable foreign exchange rates, maintaining strong demand in the first line biologic inflammatory bowel disease (“IBD”) population and continued patient gains after the launch of the subcutaneous formulation. Sales in Europe and Canada were JPY 169.8 billion (JPY +26.7 billion and +18.7% AER). The increase was primarily due to continued patient gains by an increased use of the subcutaneous formulation and favorable foreign exchange rates.

Sales of GATTEX/REVESTIVE (for short bowel syndrome) were JPY 113.3 billion (JPY +23.3 billion and +25.9% AER, +20.0% CER). The increase was primarily due to increased demand in the U.S., expansion activities (pediatric indication label expansion), and favorable exchange rates.

<div align='center'>3</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Nine-month

Period Ended December 31, 2024 (Consolidated)

#### Rare Diseases
In Rare Diseases, revenue was JPY 579.0 billion (JPY +54.7 billion and +10.4% AER, +4.9% CER).

Sales of TAKHZYRO (for hereditary angioedema) were JPY 168.0 billion (JPY +31.6 billion and +23.2% AER, +16.4% CER). The increase was primarily due to higher demand in the U.S., Europe and Canada supported by strong patient persistency and prophylactic market growth, as well as favorable foreign exchange rates.

Sales of enzyme replacement therapy ELAPRASE (for Hunter syndrome) were JPY 77.1 billion (JPY +7.2 billion and +10.2% AER, +5.2% CER). The increase was primarily due to strong demand in the Growth and Emerging Markets and Europe, and favorable foreign exchange rates